Refractory Hemochromatosis Rheumatism
Conditions
Keywords
hereditary haemochromatosis, rheumatism, anakinra
Brief summary
Treatment of refractory hemochromatosis rheumatism by Anakinra. Prospective, multicenter, non-randomised, single-arm, open-label, phase II trial.
Detailed description
Hereditary hemochromatosis (HH) is a genetic disease characterized by tissue iron overload. The most common genotype is homozygosity for the p.Cys282Tyr mutation of the HFE gene (MIM 235200). It is a serious disease which can lead to life threatening complications such as cirrhosis, liver carcinoma, heart failure or diabetes mellitus. Currently, these complications can be prevented by phlebotomies. Two-thirds of patients complain of joint symptoms which represent a major cause of impaired quality of life. Phlebotomies are ineffective on HH rheumatism and patients' quality of life is very often altered while life threatening complications are prevented. Furthermore, there is a significant higher risk for joint replacement surgery in these patients compared to controls (X 9). There is currently no approved treatment for hemochromatosis rheumatism. As it looks like severe osteoarthritis, calcium pyrophosphate deposition disease (CPDD) or chondrocalcinosis, symptomatic treatments are employed such as analgesics (type I or II), non-steroidal anti-inflammatory drugs or colchicine in case of acute joint flare, corticosteroids intra-articular injections or occasionally oral glucocorticoids. However in some cases these treatments remain ineffective leading to a true disability. Frequently, there are local inflammatory symptoms. Interleukin 1ß (IL1ß) plays a key role in the pathogenesis of crystal arthropathies (CPDD or gout). Anakinra (IL-1Ra), a drug approved in France for rheumatoid arthritis, has been tested in short series or case controls in refractory gout, CPDD and only in two patients with HH rheumatism. The aim of this phase II study is to test the efficacy of anakinra in patients with hemochromatosis and refractory joint pain. It is also to evaluate the opportunity to perform a phase III trial. In the absence of available data on the evolution of this rheumatism treated by anakinra in this population of patients resistant to standard therapy, the investigators consider that a phase III trial would not be justifiable if the rate of success is insufficient.
Interventions
DRUGAnakinra
One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
Sponsors
Rennes University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with age equal to or over 18 years old, * Patients with proved hereditary hemochromatosis with homozygosity for the C282Y mutation of the HFE gene, * Patients with rheumatism related to hemochromatosis, considered by the rheumatologist refractory to usual treatment defined by a persistent painful symptomatology despite a treatment of at least one month with level 2 analgesics (weak opioids) at maximal dose, NSAID, colchicine, steroid injection or a combination of these treatments, * Patients with pain \> 40/100mm measured by VAS (pain of the last 48 hours), * Effective contraception to be used during treatment and until 48h after the last administration for women of reproductive age, * Patients who have given written informed consent.
Exclusion criteria
* Other cause of inflammatory rheumatisms such as Rheumatoid Arthritis, Spondyloarthropathies, psoriatic arthritis, or systemic diseases, * Ongoing treatment with Methotrexate, Hydroxychloroquine, biologic or immunosuppressive drugs * Malignant pathology, monoclonal gammopathy, * Intolerance to anakinra, * Contraindications to the use of anakinra: pregnancy or breastfeeding, hypersensitivity to any of the excipients or to proteins from E. coli, severe renal impairment (creatinine clearance \<30 ml / minute), neutropenia (neutrophil count \<1.5 x 109 / l), ongoing infection * Patients that cannot follow the protocol, * Persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of patients with improvement of joint pain | Day 15 | Improvement is defined as the minimal clinically important improvement of joint pain and is assessed on a 0-100 mm visual analogue scale (VAS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma clearance after administration (CL/F) of anakinra | Predose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 15, 18, 21, 24 hours post-dose | Pharmacokinetics study |
| Assessment of the disease activity | Day 0, day 15, day 30, day 60, day 90 | Assessment of the disease activity by Visual analog scale (VAS) |
| Assessment of the number of painful joints | Day 0, day 15, day 30, day 60, day 90 | Assessment of the number of painful joints by a clinical exam |
| Assessment of the number of swollen joints | Day 0, day 15, day 30, day 60, day 90 | Assessment of the number of swollen joints by a clinical exam |
| Assessment of analgesics consumption | Day 0, day 15, day 30, day 60, day 90 | — |
| Assessment of non-steroidal anti-inflammatory drugs (NSAID) consumption | Day 0, day 15, day 30, day 60, day 90 | — |
| Assessment of colchicine consumption | Day 0, day 15, day 30, day 60, day 90 | — |
| Assessment of steroids injections consumption | Day 0, day 15, day 30, day 60, day 90 | — |
| Area under the concentration-time curve of time 0 to infinity (AUC0-∞) of anakinra | Predose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 15, 18, 21, 24 hours post-dose | Pharmacokinetics study |
| Functional evaluation | Day 0, day 15, day 30, day 90 | Functional evaluation by WOMAC index for hip and knee |
| Assessment of joint damage | Day 0, day 90 | Assessment of joint damage by X-rays and Doppler ultrasound |
| Synovial fluid analysis | 3 months | Puncture if acute joint effusion : cells count |
| Biological effects on inflammation and iron metabolism | Day 0, day 15, day 30, day 60, day 90 | Biological/Vaccine : iron and inflammatory markers |
| Time at which Cmax of anakinra was observed (Tmax) | Predose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 15, 18, 21, 24 hours post-dose | Pharmacokinetics study |
| Maximum observed concentration (Cmax) of anakinra | Predose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 15, 18, 21, 24 hours post-dose | Pharmacokinetics study |
| Half-life (T1/2) of anakinra | Predose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 15, 18, 21, 24 hours post-dose | Pharmacokinetics study |
| Area under the concentration-time curve of time 0 to the last detectable concentration (AUC0-last) of anakinra | Predose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 15, 18, 21, 24 hours post-dose | Pharmacokinetics study |
| Assessment of the quality of life | Day 0, day 15, day 30, day 90 | Assessment of the quality of life by the SF36 questionnaire |
Countries
France
Outcome results
None listed